CONTACT US: Contact info
|
Citation |
Chapman JL, Serinel Y, Marshall NS, Grunstein RR. Sleep Med. Clin. 2016; 11(3): 353-363. |
|
Affiliation |
NeuroSleep Centre of Research Excellence, Woolcock Institute of Medical Research, Sleep and Circadian Research Group, University of Sydney, Glebe Point Road, Glebe, Sydney, New South Wales 2050, Australia; Respiratory and Sleep Department, Royal Prince Alfred Hospital, Sydney Local Health District, Missenden Road, Camperdown, Sydney, New South Wales 2050, Australia. |
|
Copyright |
(Copyright © 2016, Elsevier Publishing) |
|
DOI |
|
PMID |
27542881 |
|
Abstract |
Excessive daytime sleepiness (EDS) is common in obstructive sleep apnea (OSA), but it is also common in the general population. When sleepiness remains after continuous positive airway pressure (CPAP) treatment of OSA, comorbid conditions or permanent brain injury before CPAP therapy may be the cause of the residual sleepiness. There is currently no broad approach to treating residual EDS in patients with OSA. Individual assessment must be made of comorbid conditions and medications, and of lifestyle factors that may be contributing to the sleepiness. Modafinil and armodafinil are the only pharmacologic agents indicated for residual sleepiness in these patients. Language: en |